A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223391

Enrollment

Registered

2016-11-25

Start date

2016-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Tumors

Interventions

investigational material(s) Generic name etc : MEDI9090, Durvalumab INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Must have histologic documentation of advanced solid tumors - Must have received and have progressed, are refractory or, intolerant to standard therapy and must not have a curative therapy option

Exclusion criteria

Exclusion criteria: - Concurrent enrollment in another clinical study - Prior participation in clinical studies that include durvalumab alone or in combination - Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment

Design outcomes

Primary

Measure	Time frame
safety -	—

Secondary

Measure	Time frame
safety pharmacokinetics -	—

Countries

Japan, North America

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026